Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shufeng Huoluo Pill (疏风活络丸) is a traditional Chinese medicine (TCM) formulation manufactured by Changchun Leiyunshang Pharmaceutical, a subsidiary of the historic Leiyunshang Pharmaceutical Group. This oral pill is an approved pharmaceutical product in China, primarily indicated for conditions traditionally described as 'wind-dampness' obstruction, which typically correlate with rheumatic pain, joint stiffness, and limb numbness. The formulation contains several active alkaloid compounds, including pseudoephedrine, ephedrine, strychnine, and brucine. Following TCM theory, the drug is designed to expel pathogenic wind, transform phlegm, and activate the collaterals to alleviate pain and improve mobility. While the specific molecular targets are not formally defined in its regulatory approval, the presence of potent alkaloids suggests a complex pharmacological profile typical of modernized TCM preparations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shufeng Huoluo Pill.